GI cancers – rapid oral abstracs in ASCOBT 24 summarized by Erman Akkus

Erman Akkus, Medical Oncology Fellow at Ankara University Faculty of Medicine, shared on X:

“GI cancers- rapid oral abstracts in ASCOBT (Breakthrough) 24.

• 221- The impact of HRD mutation on survival in patients with KRAS-mutated advanced pancreatic cancer.

HRD+ve pts had better time-to-treatment failure when treated with mFOLFIRINOX, but not with gemcitabine-nab-paclitaxel.

• 196- Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial).

Bite-on-bite biopsies and EUS-FNA for lymph nodes are accurate, ctDNA may help.

• 50- Outcomes in Child-Pugh (CP) B liver function treated with atezolizumab plus bevacizumab (A+B) for hepatocellular carcinoma (HCC).

No additional safety risks, may still benefit.

• 34- Phase Ib trial of durvalumab plus tremelimumab in combination with particle therapy in advanced HCC with macrovascular invasion: Departure.

The combination is safe.”

Source: Erman Akkus/X

Other posts featuring Erman Akkus on OncoDaily.